meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced OC (mOC) - 1st line (L1)
1
mOC - L1 - all population
1
mOC - L1 - PDL1 positive
1
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus SoC
versus all
vs chemotherapy
vs Standard of Care (SoC)
vs placebo plus SoC
All patients
Age > 65y
Asian type
ECOG 0
ECOG 1
PDL1 (TC0 and IC0 : <1% of TC and IC)
PDL1 (TC1/2 or IC1/2 : ≥1% of TC or IC and <50% of TC and <10% of IC)
PDL1 (TC2/3 or IC2/3 : ≥5% of TC or IC)
stage III (locally advanced)
stage IV (metastatic)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
deaths (OS)
objective responses (ORR)
progression or deaths (PFS)
AE (any grade)
AE (grade 3-4)
AE leading to death (grade 5)
AE leading to treatment discontinuation (any grade)
SAE (any grade)
STRAE (any grade)
TRAE (any grade)
TRAE (grade 3-4)
TRAE leading to death (grade 5)
Adrenal insufficiency TRAE (grade 3-4)
Colitis TRAE (grade 3-4)
Diabetes TRAE (grade 3-4)
Guillain-Barré syndrome TRAE (grade 3-4)
Hepatitis TRAE (grade 3-4)
Hypothyroidism TRAE (grade 3-4)
Infusion-related reactions TRAE (grade 3-4)
Myocarditis TRAE (grade 3-4)
Myositis TRAE (grade 3-4)
Nephritis TRAE (grade 3-4)
Pancreatitis TRAE (grade 3-4)
Pneumonitis TRAE (grade 3-4)
Rash TRAE (grade 3-4)
Severe skin reaction TRAE (grade 3-4)
Acute kidney injury AE (grade 3-4)
Decreased appetite AE (grade 3-4)
Dyspnoea AE (grade 3-4)
Hypertension AE (grade 3-4)
Infusion-related reaction AE (grade 3-4)
Proteinuria AE (grade 3-4)
deaths (OS)
mOC - L1 - all population
metastatic/advanced OC (mOC) - 1st line (L1)
mOC - L1 - all population
versus placebo plus SoC
atezolizumab plus SoC vs. placebo plus SoC
1
certainty unassessable
-4%
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open